Biosimilars Market | Ongoing Trends and Recent Developments | Major Key Players like Pfizer (US), Sandoz International (Germany), Teva Pharmaceuticals (Israel), Amgen (US), Biocon (India)

Growth in this Biosimilars Market is mainly driven by factors such as the rising incidence of chronic diseases and increasing demand for biosimilar drugs due to their cost-effectiveness.

What the Market Looks Like?

Predicted to grow at a CAGR of 31.7% during the forecast period, the global Biosimilars Market is estimated to reach USD 23.63 Billion by the end of 2023. In 2017, Europe accounted for the largest share of the global market.

By product, the Biosimilars Market is classified into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. Recombinant glycosylated proteins are expected to hold the largest share of the market during the forecast period. The key factors driving the market for glycosylated proteins are the broad therapeutic area of these proteins and the presence of biosimilar versions of monoclonal antibodies at lower prices compared to reference products.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40

By type of manufacturing, the market is segmented into in-house manufacturing and contract manufacturing. In-house manufacturing accounted for the largest share of the global Biosimilars Market in 2017. The growing demand for cost-effective biosimilar products owing to the rising incidence of various diseases is driving the growth of the in-house manufacturing segment

By disease, this market is sub-segmented into oncology, chronic diseases, autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and other diseases. The autoimmune disease segment is expected to grow at the highest growth rate during the forecast period. Increasing incidences of autoimmune diseases and the increasing number of product launches by companies in this market are the major factors driving the growth of this segment.

What Drives the Biosimilars Market?

The growth of the global market for Biosimilars is primarily influenced by the following factors:

• Increasing Demand for Biosimilar Drugs Due to Their Cost-Effectiveness
• Rising Incidence of Chronic Diseases
• Strategic Collaborations Resulting in Enhanced Productivity and Clinical Trial Activities for Biosimilars
• New Indications and Patent Expiry of Biologic Products

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=40

Geographical growth scenario of Biosimilars Market:

The global market is geographically segmented into North America, Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the highest CAGR during the forecast period. Many Asian countries such as India, China, South Korea, and Japan have emerged as potential markets for biosimilars. Many emerging economies in the region are also establishing biosimilar pathways.

Moreover, leading market players are outsourcing manufacturing and R&D activities to countries in the Asia Pacific region due to the availability of highly skilled resources at lower costs. In addition to this, the low per capita consumption, rapid growth in economies, trade links, and the rise in medical tourism are accelerating the growth of the Asian market.

Read More in Detailed: https://www.marketsandmarkets.com/PressReleases/global-biosimilars-product-market-worth-19.4-billion-by-2014.asp

Leading market players and strategies adopted:

The prominent players in the Biosimilars Market include Pfizer (US), Sandoz International (Germany), Teva Pharmaceuticals (Israel), Amgen (US), Biocon (India), Dr. Reddy’s Laboratories (India), Celltrion (South Korea), and Samsung Biologics (South Korea).

Contact Us:

Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

About MarketsandMarkets™:

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.